revenue $1.22B, net income $181.9M. Bio-Techne agrees to /share Merck KGaA buyout; FY26 net income +148% on non-operating items

Filed August 24, 2026 · Period ending June 30, 2026 · Compared to 10-K Aug 22, 2025 · ~2 min read

Key Changes

• high

  Definitive merger with Merck KGaA announced June 2026: shareholders receive $73.00/share cash, subject to regulatory approvals and shareholder vote, expected close late 2026 or early 2027. No-shop provisions and $230.5M termination fee limit competing bids.

  Risk Factors / Notes: Merger Agreement verify on EDGAR →
• high

  Net income rose 147.8% to $181.9M (diluted EPS +152.2% to $1.16) while operating income climbed 146% to $251.9M, driven by absence of prior-year $80.5M asset impairment and $41.8M arbitration charge, plus a $6.1M recovery on assets held-for-sale. Adjusted net earnings fell 1% on unfavorable product mix and pricing pressures.

  MD&A: Consolidated Earnings verify on EDGAR →
• high

  Revenue flat at $1.22B (-0.4%): Protein Sciences organic revenue fell 1% (vs +5% prior year) on product mix and pricing headwinds; Diagnostics organic +4% (vs +6%) but reported -3% after Exosome Diagnostics divestiture (-8% impact). Adjusted gross margin compressed 80bp to 69.6%.

  MD&A: Revenue & Margins verify on EDGAR →